We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Aug 5 - Vertex Pharmaceuticals (NASDAQ:VRTX) shares dropped nearly 17% on Tuesday after its experimental pain medication, ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...